Long-Term Single-Dose Efficacy of a Vesicular Stomatitis Virus-Based Andes Virus Vaccine in Syrian Hamsters
Andes virus (ANDV) is highly pathogenic in humans and is the primary etiologic agent of hantavirus cardiopulmonary syndrome (HCPS) in South America. Case-fatality rates are as high as 50% and there are no approved vaccines or specific therapies for infection. Our laboratory has recently developed a...
Main Authors: | Joseph Prescott, Blair L. DeBuysscher, Kyle S. Brown, Heinz Feldmann |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2014-01-01
|
Series: | Viruses |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4915/6/2/516 |
Similar Items
-
Vesicular Stomatitis Virus-Based Vaccines Provide Cross-Protection against Andes and Sin Nombre Viruses
by: Bryce M Warner, et al.
Published: (2019-07-01) -
Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model
by: James Duehr, et al.
Published: (2020-03-01) -
First Human Isolate of Hantavirus (Andes virus) in the Americas
by: Hector Galeno, et al.
Published: (2002-07-01) -
Therapeutic Efficacy of Human Monoclonal Antibodies against Andes Virus Infection in Syrian Hamsters
by: Brandi N. Williamson, et al.
Published: (2021-10-01) -
Andes Virus and First Case Report of Bermejo Virus Causing Fatal Pulmonary Syndrome
by: Paula Padula, et al.
Published: (2002-04-01)